Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Application
Item No. 24428

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
C18 dihydro Ceramide-d3 is intended for use as an internal standard for the quantification of C18 dihydro ceramide (d18:0/18:0) (Item No. 24379) by GC- or LC-MS. C18 dihydro Ceramide is a bioactive sphingolipid and precursor in the de novo synthesis of C18 ceramide (d18:1/18:0) (Item No. 19556) that lacks the 4,5-trans double bond.1 Increased C18 dihydro ceramide lipid levels lead to increased triacylglycerol storage and autophagosome accumulation as well as upregulation of the fibrosis markers α-SMA and FGF2 in Chang and LX-2 liver cells. C18 dihydro Ceramide is elevated in the plasma of pre-diabetics up to 9 years prior to the onset of type 2 diabetes.2 It is also elevated in the skin of patients with lesional atopic dermatitis.3
WARNING This product is not for human or veterinary use.
1. Dihydroceramide is a key metabolite that regulates autophagy and promotes fibrosis in hepatic steatosis model. Biochem. Biophys. Res. Commun. 494(3-4), 460-469 (2017).
2. Plasma dihydroceramides are diabetes susceptibility biomarker candidates in mice and humans. Cell Rep. 18(9), 2269-2279 (2017).
3. Relationship of ceramide-